is clearly more important than using a highly potent bisphosphonate treatment regimen. Langston, A. L. et al. Randomised trial of intensive bisphosphonate treatment versus symptomatic management ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

Relapse is also quicker when less potent agents and lower doses are used. The phenomenon of relapse indicates that bisphosphonates do not prevent the recruitment of osteoclasts. The kinetics of ...

receiving daily oral prednisolone were randomly assigned to receive one intravenous infusion of the potent bisphosphonate zoledronate (5 mg) followed by daily oral placebo, or a placebo infusion ...